Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

tients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75 percent and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: ... in the development, manufacturing, and marketing of branded,generic ... 105 of,its drugs have been included in China,s ... China,s Ministry of Human Resources and Social,Security on ...
(Date:12/2/2009)... is going through,extraordinary times; markets are in turmoil and ... out that the pharma industry has been,relatively immune to ... During the midst of the ... inaugurated an R&D center in Shanghai, the largest of,its ...
(Date:12/2/2009)... to the National Institute of Health, 40 percent to 45 ... of diabetic retinopathy. Diabetic retinopathy, damage to the retina ... blindness in people with diabetes and is one of the ... percent of all patients who,ve had diabetes for 10 years ...
(Date:12/1/2009)... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... 2009 of approximately $57 million, as compared with $69 million ... 2008 results was the first of two installment payments of ... 2008 results was a one-time $1.8 million payment from Genentech ...
Breaking Biology Technology:Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
... Wis. - Quintessence Biosciences , a biopharmaceutical ... of its EVade cancer treatments, has been selected for ... said that pending a favorable preclinical safety assessment, it ... Administration an investigational new drug application in late ...
... the word sustainability in a crowd of business executives ... you as an aging hippie, then scrambled away to ... , ,Today, sustainability still carries some linguistic baggage, but ... because there's no avoiding a rational conversation. Global climate ...
... - Every week, we read high-profile stories about ... a laptop computer or computer network. This sensitive information ... and the government, with little accountability for such security ... knights in shining armor, the Wisconsin Legislature ...
Other Biology Technology:Re-engineering our economy to be sustainable and profitable 2Re-engineering our economy to be sustainable and profitable 3Re-engineering our economy to be sustainable and profitable 4Wisconsin identity theft law: A cheap plastic sword 2Wisconsin identity theft law: A cheap plastic sword 3
(Date:12/3/2009)... undergo a personality change in warmer water, according to an ... species more aggressive. , Experiments with two species of young ... first time that some reef fish are either consistently timid, ... more marked as water temperatures rise. , A slight lift ...
(Date:12/3/2009)... comes to investment in energy efficient technologies research, but ... Dave Delpy believes that more is needed: "Scientific and ... wind and solar power solutions, but more investment is ... we are to meet our carbon emission targets by ...
(Date:12/2/2009)... PHILADELPHIA Less acculturated Latino men have a more ... acculturated to U.S. culture, but acculturation has no affect ... findings are published in Cancer Epidemiology, Biomarkers & ... Cancer Research. The December issue has a special focus ...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Animes fan girls 49360 1Animes fan girls 49360 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 1Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 3Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 4Wound Care Certification Program Gives Healthcare Sales Professionals Competitive Edge in Tough Economy 49355 1
... Tomorrow, PETA will donate $120,000 to the Duluth-based ... its important work aimed at improving toxicity testing and ... routinely maimed and killed in laboratory experiments. PETA will ... 25, at the Inn on Lake Superior in Duluth. ...
... to have a profound impact on human physiology as ... new study led by researchers from the Biodesign Institute ... passengers flown in spacemicrobescan be equally affected by space ... alters cellular and physiological responses in astronauts including the ...
... Hamilton, ON. Sept. 24, 2007 Men who have ... high-pitched voices, researchers have found. And their study ... with low-pitched voices. , The study, published in Biology ... voice as well as how we choose our mates. ...
Other Biology News:PETA awards $120,000 to Duluth Foundation for advancing non-animal tests 2Spaceflight shown to alter ability of bacteria to cause disease 2Spaceflight shown to alter ability of bacteria to cause disease 3Spaceflight shown to alter ability of bacteria to cause disease 4
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: